Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Ischaemic heart disease
Folate as a way to reduce in-stent restenosis ▸ Plasma homocysteine has been recognised as an important cardiovascular risk factor. Several groups have found a link between homocysteine concentrations and angiographic restenosis within stents. A trial of 553 patients assigned to lowering of homocysteine with B12 (400 μg/day), folate (1 mg/day), and pyridoxine (10 mg/day) versus placebo suggests benefit at one year. The combined end point of death/myocardial infarction/repeat revascularisation showed a relative risk (RR) of 0.68 on treatment (15.4% v 22.8%; p = 0.03), primarily caused by a reduced rate of target lesion revascularisation (9.9% v 16.0%, RR 0.62, 95% confidence interval (CI) 0.40 to 0.97; p = 0.03).
CABG or PTCA for isolated proximal LAD lesions? ▸ With improvements in technology, coronary angioplasty (PTCA) can be safely done in many cases which would previously have required surgery. Minimally invasive left internal mammary artery (LIMA) grafting (MIBCAB) has also reduced the risks of coronary artery bypass grafting (CABG). In 220 patients randomised to either PTCA and stenting, or MIBCAB, the surprising fact was the rate of death/myocardial infarction/revascularisation at six months was as high as 15% in the surgery group. This was better than the 31% in the PTCA group (p = 0.02). High restenosis rates after stenting (29% v 8%, p = 0.003) were the problem; rates of death and myocardial infarction did not differ significantly between groups (3% in the stenting group and 6% in the surgery group, p = 0.50). The percentage of patients free from angina after six months was 79% in the surgery group, as compared with 62% in the stenting group (p = 0.03). However, this could also be interpreted to mean that nearly two thirds of patients could safely avoid CABG. The choice is personal, but drug eluting stents may shift the balance towards PTCA in the future.
Abciximab and tirofiban are equivalent in non-diabetic patients ▸ Independently shown to reduce major adverse event rates after PTCA and stenting, the TARGET trial is the only head-to-head comparison of tirofiban and abciximab. A total of 4809 patients undergoing elective or urgent stent implantation were randomly assigned a bolus and infusion of tirofiban or abciximab. Event rates at 30 days favoured abciximab, but at six months, the composite end point of death, myocardial infarction, and target vessel revascularisation occurred in 356 (14.8%) patients who received tirofiban and 345 (14.3%) patients who received abciximab (hazard ratio 1.04, 95% CI 0.90 to 1.21; p = 0.591). There were no differences in any individual end points, including restenosis. Data in diabetic patients is still much stronger for abciximab, however.
Perhaps statins are not as well tolerated as we think ▸ There were 22 379 patients in the acute coronary syndrome (ACS) cohort, 36 106 in the chronic coronary artery disease (CAD) cohort, and 85 020 in the primary prevention cohort over 66 years of age who had been prescribed statins at least once. Two year adherence rates in the cohorts were only 40.1% for ACS, 36.1% for chronic CAD, and 25.4% for primary prevention. Two possible explanations are that the physicians were not continuing prescription through lack of belief in long term benefits, or the drugs are not well tolerated by the elderly. Patients with ACS appeared more likely to continue than others.
Obesity doubles the risk of heart failure ▸ Among 5881 participants in the Framingham heart study (mean age 55 years, 54% women), 496 developed heart failure. After adjustment for established risk factors, there was an increase in the risk of heart failure (5% for men and 7% for women) for each increment of 1 in body mass index. As compared with subjects with a normal body mass index, obese subjects had a doubling of the risk of heart failure.
Iron overload as detected by MRI decreases with oral iron chelation ▸ Despite the introduction of the parenteral iron chelator desferrioxamine more than 30 years ago, 50% of patients with thalassaemia major die before the age of 35 years, predominantly from iron induced heart failure. The only alternative treatment is oral deferiprone, but its long term efficacy on myocardial iron concentrations is unknown. Myocardial iron content and cardiac function was assessed in 15 patients receiving long term deferiprone treatment with 30 matched thalassaemia major controls who were on long term treatment with desferrioxamine. Myocardial iron concentrations were measured by a new magnetic resonance T2* technique, which shows values inversely related to tissue iron concentration. The deferiprone group had significantly less myocardial iron (p = 0.02) and higher ejection fractions (mean (SD) 70 (6.5)% v 63 (6.9)%, p = 0.004) than the desferrioxamine controls.
Inhaled iloprost has some benefit in pulmonary hypertension ▸ Intravenous iloprost is known to reduce mortality in primary pulmonary hypertension. In this study, repeated daily inhalations of 2.5 or 5.0 μg of iloprost (six or nine times per day; median inhaled dose, 30 μg per day) were compared with inhalation of placebo. A total of 203 patients with severe pulmonary arterial hypertension (New York Heart Association (NYHA) functional class III or IV) were included. Clinical criteria of improvement were present in 16.8% of the patients receiving iloprost, as compared with 4.9% of the patients receiving placebo (p = 0.007). NYHA class (p = 0.03), dyspnoea (p = 0.015), and quality of life (p = 0.026) also improved. No mortality reduction was seen.
Rub rather than wash ▸ We are poor at handwashing between patients when in outpatients. This trial compared the efficacy of handrubbing with an alcohol based solution versus conventional handwashing with antiseptic soap in reducing hand contamination during routine patient care. Bacterial counts were taken from handprints after cleaning. With handrubbing the median percentage reduction in bacterial contamination was significantly higher than with handwashing (83% v 58%, p = 0.012), with a median difference in the percentage reduction of 26% (95% CI 8% to 44%). The median duration of hand hygiene was 30 seconds in each group.
Rub rather than scrub ▸ The correct way to clean your hands before putting on sterile gloves has always been to scrub with iodine or chlorhexidine solutions. Surgical services used two hand cleansing methods alternately every other month: a handrubbing protocol with 75% aqueous alcoholic solution containing propanol-1, propanol-2, and mecetronium etilsulfate; and a handscrubbing protocol with antiseptic preparation containing 4% povidone iodine or 4% chlorhexidine gluconate. Surgical site infection rates at 30 days were 55 of 2252 (2.44%) in the handrubbing protocol and 53 of 2135 (2.48%) in the handscrubbing protocol (p = ns). Compliance with the recommended duration of hand antisepsis was better in the handrubbing protocol of the study compared with the handscrubbing protocol (44% v 28%, respectively; p = 0.008), as was tolerance, with less skin dryness and less skin irritation after aqueous solution use.
Oral vitamin K is better than subcutaneous for controlling high INR on warfarin ▸ Patients with an international normalised ratio (INR) between 4.5 and 10.0 were randomised to 1 mg vitamin K orally or subcutaneously. In 15 of 26 patients receiving oral vitamin K and 6 of 25 patients receiving subcutaneous vitamin K, therapeutic INRs were achieved on the day after study drug administration (odds ratio 4.32, 95% CI 1.13 to 17.44; p = 0.015). Intravenous vitamin K was not tested, but has risks associated with it.
American Journal of Medicine; American Journal of Physiology: Heart and Circulatory Physiology; Annals of Emergency Medicine; Annals of Thoracic Surgery; Archives of Internal Medicine; BMJ; Chest; European Journal of Cardiothoracic Surgery; Lancet; JAMA; Journal of Clinical Investigation; Journal of Diabetes and its Complications; Journal of Immunology; Journal of Thoracic and Cardiovascular Surgery; Nature Medicine; New England Journal of Medicine; Pharmacoeconomics; Thorax
C Baker, E Barnes, V Bhatia, R Desilva, M Earley, K Fox, D Gorog, G Jenkins, R Kaprilian, A Kapur, M Khan, P Lambiese, V Markides, M Poullis, P Ramrakha, J Strange, B Wasan, H Walker